Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

Exclusion Criteria

• •Unstable medical conditions:
• •* Heart disease
• •* Seizures
• •* Cancer
• •* Thyroid disease (okay if controlled with medication)
• •* Diabetes
• •* Hepatitis B or C or Liver disease
• •* Glaucoma
• •* Kidney disease or urinary retention
• •* An ulcer in the past year
• •* Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)
• •Hypertension if uncontrolled (meaning participant has a diagnosis, but they are not taking medication/under treatment (e.g., diet or exercise plan)
• •Drug/Alcohol Dependence
• •* Alcohol or illicit drug dependence within the past 12 months (currently in treatment) with the exception of those who recently completed an alcohol/drug treatment program
• •* Positive toxicology test at the screening visit (THC \& prescribed medications okay)
• •* Opioid replacement therapy (including methadone, buprenorphine, or other)
• •Psychiatric conditions
• •* Current or past schizophrenia, and/or current or past bipolar disorder
• •* Major depression, current or within the past year
• •* Major personality disorder
• •* Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the PI \[study physician\] and considered for inclusion
• •* History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per PI's \[study physician's\] approval
• •Current regular use of any psychiatric medications with the exception of Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate
• •Congenital or acquired immunodeficiency disorders (i.e. HIV, congenital immune deficiency syndrome, chronic diseases)
• •Other disorders (i.e. ICU, malnutrition, immunosuppressive therapy)
• •Traumatic brain injury
• •Recent onset or change (worsening) in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks
• •Medications
• •* Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs)
• •* Concurrent use of nicotine-containing medications
• •* Any stimulant medications (ex. Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment
• •Other/Misc. Chronic Health Problems
• •* Oral thrush
• •* Fainting
• •* Other "life threatening illnesses" as per study physician's discretion
• •Pregnancy
• •* Pregnancy (self-reported and urine pregnancy test)
• •* Breastfeeding (determined by self-report)
• •Concurrent participation in another clinical trial
• •Inability to communicate in English
• •History of marijuana-induced psychosis or paranoia after smoking marijuana
• •Scoring a 7 or higher on the Severity of Dependence Scale (SDS) for cannabis use
• •Planning to quit smoking or vaping within the next 60 days
• •Planning to quit cannabis use within the next 60 days
• •Uncomfortable with getting blood drawn
• •Willingness to abstain from tobacco smoking and all combustible products for 13 hours before admission
• •Willingness to abstain from smoking/ingestion of cannabis 13 hours before
• •Willingness to abstain from nicotine products 13 hours before each admission